Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Durability of Protection and Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Women Aged 18 to 45 Years

NCT05045755 is registered in ClinicalTrials.gov with Jun Zhang as lead sponsor.

NCT NCT05045755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05045755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Durability of Protection and Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Women Aged 18 to 45 Years
Lead sponsor
Jun Zhang
Phase
Observational
Overall status
Unknown status
Start date
April 13, 2021
Completion date
January 31, 2024
Enrollment
1,339 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cervical intraepithelial neoplasia, persistent infection, vaginal intraepithelial neoplasia, vulvar intraepithelial neoplasia